A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 (NCT06062420)
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (108 Sites)
Showing the first 25 of 108 sites.
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Iowa City, Iowa
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — Columbus, Ohio
- GSK Investigational Site — Milwaukee, Wisconsin
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Capital Federal,
- GSK Investigational Site — Ciudad Autonoma de Bueno,
- GSK Investigational Site — Córdoba,
- GSK Investigational Site — Florida,
- GSK Investigational Site — Mendoza,
- GSK Investigational Site — San Juan,
- GSK Investigational Site — Santa Fe,
- GSK Investigational Site — Santo André,
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — Calgary, Alberta
- GSK Investigational Site — Edmonton, Alberta
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Montreal, Quebec
- GSK Investigational Site — Herlev,
- GSK Investigational Site — Turku,
- GSK Investigational Site — Bordeaux,
- GSK Investigational Site — Caen,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasms, Head and Neck
Explore by condition: All Neoplasms, Head and Neck clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.